News List

Bagel Biologics receives approval to initiate Phase I clinical trial of TCR cell therapy

On September 9, 2023, Biosyngen Pte Ltd (hereinafter referred to as "Biosyngen") announced

Researchers at Zhejiang University School of Medicine have revealed that the concept of targeting DDK can improve the efficacy of immunotherapy for liver cancer

Hepatocellular carcinoma is a common and highly aggressive tumor that has been recognized as the sev

On July 14, Bojian's listing application for tofersen injection was accepted.

On April 25, 2023, the FDA accelerated approval of the antisense oligonucleotide therapy tofersen (Q

The annual bleeding rate of patients was reduced by 71%, and Pfizer's marketing application for hemophilia gene therapy was accepted by the FDA

Pfizer, Inc. (NYSE: PFE) today announced that the FDA has accepted a biologics license application (

FDA approves First repeatable drug gene Therapy, $630,000 a Year, for 'most painful diseases'

On May 19, 2023, the FDA approved Beremagene Geperpavec (B-VEC), a topical gene therapy based on the

Wang Ben's team at Zhejiang University developed fluorine-containing polymer assembly drugs to achieve chemotherapeutic-immune cascade cancer therapy

Recently, Wang's research group from the Institute of Translational Medicine of Zhejiang Univers

The first patient administration of the new NASH drug, Kylo-0603, was completed in Phase I in China

On March 28, 2023, Kylo-0603, a thyroxine receptor-β (THR-β) agonist drug independently developed by

China's first personalized tumor newborn antigen vaccine has been approved by NMPA to enter the clinical stage

On March 15, 2023, the website of the Center for Drug Review and Evaluation (CDE) of the State Medic

The world's second! FDA grants Pfizer priority review for CD3/BCMA bispecies

Pfizer announced that the U.S. Food and Drug Administration (FDA) has granted priority review status

The FDA accelerated its approval of Bruton's kinase inhibitor Jaypirca

2023 The first fluorine-containing drug was approved. 2023.01.27 Eli Lilly's Loxo Oncology annou